IP Library › Granted Patent US 10,166,266
Granted Patent B2
US 10,166,266 · App. 15/958,654 · Granted Jan 1, 2019

Process to enhance the bioactivity of ashwagandha extracts

Inventor: Benny Antony (Angamaly, IN)
A61K36/81A61K9/14A61K9/2846A61K9/5026A61K9/5036A61K9/5042A61K36/185A61K36/23A61K36/47A61K36/48A61K36/53A61K36/534A61K36/54A61K36/67A61K36/71A61K36/82A61K36/87A61K36/9066A61K36/9068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,266
App. No.
15/958,654
Granted
Jan 1, 2019
Kind
B2
Abstract

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

Claims (16)

1. A method of treating stress comprising administering an enteric coated composition to a subject in need thereof, the enteric coated composition comprising extract of Withania somnifera and an enteric coating material, wherein the extract of Withania somnifera comprises by weight:

at least about 3.5% withanolide glycosides,

less than about 0.1% withanolide aglycones,

less than about 0.1% alkaloids, and,

less than about 0.1% oligosaccharides,

and wherein the enteric coating material is selected from the group consisting of poly (methacrylic acid-co-methyl methacrylate), and, a combination of modified ethyl cellulose and sodium alginate.

2. The method of claim 1 , wherein the extract of Withania somnifera comprises at least about 35% withanolide glycosides by weight.

3. The method of claim 1 , wherein the extract of Withania somnifera comprises at least about 80% withanolide glycosides by weight.

4. The method of claim 1 , wherein the extract of Withania somnifera further comprises by weight:

at least about 0.1% saponins.

5. The method of claim 1 , wherein the extract of Withania somnifera further comprises by weight:

about 2.5% saponins.

6. The method of claim 1 , wherein the extract of Withania somnifera further comprises by weight:

about 10% saponins.

7. The method of claim 1 , wherein the extract of Withania somnifera further comprises by weight:

about 15% saponins, and wherein the withanolide glycosides comprise sitoindoside I to X, withanoside I to VII and withanamides.

Priority Claims (1)
IN 5691/CHE/2015 · Oct 22, 2015 · national
Continuity (4)
Division 15326450 · Jan 13, 2017
Continuation 15444669 · Feb 28, 2017
Continuation 15326450
Related Publication 20180280463A1 · Oct 4, 2018